Skip to main content
Fig. 1 | Renal Replacement Therapy

Fig. 1

From: Investigation for the efficacy of COVID-19 vaccine in Japanese CKD patients treated with hemodialysis

Fig. 1

Trial profile. As control group, 132 patients were recruited and 4 patients were excluded before first blood test because we could not obtain consent (one patient), one had immunomodulate drugs (one patient), and they could not come to our hospital (two patients). Then, 4 patients were excluded before second blood test because one had COVID-19 (one patient), one could not come to our hospital (one patient), and they started immunomodulate drugs (two patients). One patient died before third blood test. Finally 123 patients were enrolled (a). As HD group, 223 patients were enrolled and 11 patients were excluded before first blood test because we could not obtain consent (five patients), they could not come to our hospital (two patients), they did not have vaccine or have other vaccine (three patients), and one died (one patient). Then, 5 patients were excluded before second blood test because they had antibody titer over 17.8 BAU/ml before first vaccination (three patients) or died (two patients). One patient died before third blood test. Finally 206 patients were enrolled (b). HD, hemodialysis

Back to article page